To explore the potential links between the TL1A and HS by synthesizing specific immune mechanisms of HS pathogenesis with existing data of the TL1A/DR3 axis.
Key Findings:
HS is characterized by chronic inflammation and is associated with various comorbidities that significantly impact patient quality of life.
Current treatments often fail, necessitating a combination of pharmacological and surgical interventions to achieve adequate control.
TL1A plays a significant role in inflammatory diseases and is implicated in HS pathogenesis.
Anti-TL1A therapies, such as tulisokibart, are being investigated for their efficacy in HS, with promising preliminary results.
Interpretation:
The TL1A-DR3 axis may be a critical target for therapeutic intervention in HS, potentially addressing both inflammation and fibrosis through coordinated immune modulation.
Limitations:
Data specific to the role of TL1A in HS is still emerging and not fully established, highlighting the need for further research.
Current understanding of HS pathogenesis remains incomplete, necessitating more robust clinical trial data.
Conclusion:
Anti-TL1A therapies could offer a new approach to managing HS, addressing both the disease's inflammatory and fibrotic components.
